How large is the incretin effect?

It accounts for a majority of the insulin response to an oral glucose load in healthy people, which is why bypassing it intravenously produces so much less insulin.

Why do GLP-1 drugs rarely cause hypoglycaemia?

Because incretin signalling is glucose-dependent — it potentiates insulin release when glucose is high and does little when it is not.

Is the incretin effect the same as the drugs' weight effect?

No. The incretin effect describes insulin secretion. Weight reduction comes largely from delayed gastric emptying and central satiety signalling, which are separate consequences of the same receptors.

GLP-1 & Incretin Science

What Is the Incretin Effect?

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

The incretin effect is the observation that glucose taken by mouth triggers substantially more insulin secretion than an identical amount infused intravenously. The difference is caused by gut hormones — principally GLP-1 and GIP — released in response to nutrients reaching the intestine. It accounts for a majority of the insulin response to a meal.

Key facts

Definition: Extra insulin from oral vs IV glucose
Principal hormones: GLP-1 and GIP
GLP-1 source: L cells, distal small intestine and colon
GIP source: K cells, proximal small intestine
Key property: Glucose-dependent insulin release
Native GLP-1 half-life: 1–2 minutes
Degrading enzyme: DPP-4

The experiment that defines it

Give a person glucose by mouth and measure the insulin response. Then, on another occasion, infuse glucose intravenously at a rate that reproduces exactly the same blood glucose curve. The insulin response to the oral route is far larger. Since the glucose exposure was identical by construction, something other than glucose must be driving the difference — and that something is hormonal signalling from the gut.

Why the gut signals at all

It is anticipatory. The intestine detects nutrients arriving and signals the pancreas before the resulting glucose has fully entered the circulation. That head start allows insulin secretion to rise in step with absorption rather than lagging behind it. Intravenous glucose bypasses the intestine entirely, so none of that signalling occurs.

Glucose dependence is the safety-critical property

Incretins potentiate insulin secretion only when glucose is elevated. At normal or low glucose they do very little. This is why GLP-1 receptor agonists carry a low intrinsic risk of hypoglycaemia compared with insulin or sulfonylureas, which force insulin release regardless of glucose. It is a property of the physiology the drug class inherited, not something engineered into it.

What goes wrong in type 2 diabetes

The incretin effect is markedly reduced. The GIP arm in particular loses much of its insulinotropic potency, while the GLP-1 arm remains comparatively responsive to pharmacological doses. This asymmetry is a large part of why GLP-1 was pursued as a drug target first, and why the therapeutic role of GIP agonism remained contested long after GLP-1's was settled.

From physiology to pharmacology

Native GLP-1 is destroyed within one to two minutes by DPP-4, so the hormone itself was never usable. Every drug in this class is an attempt to keep GLP-1 receptor signalling going for longer — by blocking the DPP-4 cleavage site, by binding albumin to slow clearance, or by abandoning the peptide entirely for a small molecule the enzyme does not recognise.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How large is the incretin effect?: It accounts for a majority of the insulin response to an oral glucose load in healthy people, which is why bypassing it intravenously produces so much less insulin.
Why do GLP-1 drugs rarely cause hypoglycaemia?: Because incretin signalling is glucose-dependent — it potentiates insulin release when glucose is high and does little when it is not.
Is the incretin effect the same as the drugs' weight effect?: No. The incretin effect describes insulin secretion. Weight reduction comes largely from delayed gastric emptying and central satiety signalling, which are separate consequences of the same receptors.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum